NMRA - Neumora Therapeutics, Inc. Common Stock
NEXT EARNINGS:
Mar 2, 2026
(in 20 days)
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$7.25
DETAILS
HIGH:
$8.00
LOW:
$6.00
MEDIAN:
$7.50
CONSENSUS:
$7.25
UPSIDE:
142.47%
Market Cap:
499.60M
Volume:
7,905,245
Avg Volume:
1,423,428
52 Week Range:
0.611-3.25
Sector:
Healthcare
Industry:
Biotechnology
Beta:
3.25
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
110
IPO Date:
2023-09-15
EPS (TTM):
-1.53
P/E Ratio:
-6.93
Revenue (TTM):
N/A
Total Assets:
316.97M
Total Debt:
1.85M
Cash & Equiv:
142.15M
Rev Growth (5Y):
N/A
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-91.8%
Debt/Equity:
0.01
Track Record
Statements >| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Net Income | (243.79M) | (235.93M) | (130.90M) | (237.31M) | (99.27M) |
| EPS | -1.53 | -1.49 | -0.86 | -1.56 | -0.65 |
| Total Assets | 316.97M | 496.19M | 426.23M | 429.30M | 197.95M |
| Total Debt | 1.85M | 5.23M | 8.44M | 2.05M | 2.04M |
| Cash & Equivalents | 142.15M | 374.04M | 240.94M | 409.25M | 191.98M |
| Operating Cash Flow | (182.94M) | (163.28M) | (114.90M) | (75.42M) | (26.76M) |
| Free Cash Flow | (182.94M) | (163.40M) | (115.41M) | (76.24M) | (28.06M) |
| FCF per Share | -1.15 | -1.03 | -0.76 | -0.50 | -0.18 |
| Book Value | 287.06M | 469.08M | (446.85M) | (325.22M) | (94.38M) |
| Cash & ST Investments | 307.58M | 453.98M | 371.88M | 409.25M | 191.98M |
| ROC Equity | -0.85 | -0.50 | N/A | N/A | N/A |